Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 10/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 6/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | CCNC | P24863 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1847332 | 0.93 | BRAF (0.55) | BRAFCYP2D6CYP2C9RAF1MAPK10 | |
| SCHEMBL1850652 | 0.92 | BRAF (0.54) | BRAFCYP2D6CYP2C9RAF1MAPK10 | |
| SCHEMBL1847007 | 0.89 | BRAF (0.50) | BRAFCYP2D6CYP2C9RAF1MAPK10 | |
| SCHEMBL1848810 | 0.84 | BRAF (0.53) | BRAFCYP2D6CYP2C9CCNCCDK8 | |
| SCHEMBL1846559 | 0.80 | MAPK8 (0.44) | BRAFCYP2D6RAF1MAPK10CYP3A4 | |
| SCHEMBL1851520 | 0.78 | MAPK8 (0.45) | BRAFCYP2D6RAF1MAPK10CYP3A4 | |
| SCHEMBL1853000 | 0.76 | MAPK10 (0.41) | BRAFCYP2D6RAF1MAPK10MAPK14 | |
| SCHEMBL12685023 | 0.76 | BRAF (0.69) | BRAFCYP2D6CYP2C9 | |
| SCHEMBL12491252 | 0.75 | BRAF (0.58) | BRAFCYP2D6CYP2C9RAF1MAPK14 | |
| SCHEMBL1846987 | 0.75 | BRAF (0.71) | BRAFCYP2D6CYP2C9MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946250-B2 | 3,4-diarylpyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-02-03 | — | — | US | disclosed |
| CN-102105459-B | 3,4-diarylpyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL | 2014-09-10 | — | — | CN | disclosed |
| US-20140005150-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-01-02 | — | — | US | disclosed |
| US-8541575-B2 | 3,4-diarylpyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-09-24 | — | — | US | disclosed |
| EP-2324008-B1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-05-09 | — | — | EP | disclosed |
| CN-102105459-A | 3,4-diarylpyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL | 2011-06-22 | — | — | CN | disclosed |
| US-20110144068-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-06-16 | — | — | US | disclosed |
| EP-2324008-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010010154-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005150-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | MAP3K3, MAP3K19, MAP3K15 | BRAF 115/4885CYP2D6 1773/4885CYP2C9 1857/4885 |
| US-20110144068-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | MAP3K3, MAP3K19, MAP3K15 | BRAF 115/4885CYP2D6 1773/4885CYP2C9 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.